Individual investor focused upon a limited number of diversified stocks. Seeks stocks selling below fair value; favors dividend growth. Advocates fundamental investment analysis, supplemented by the technical charts. Options strategies primarily employed to generate additional income or hedge risk.
Brian Gilmartin, is a portfolio manager at Trinity Asset Management, a firm he founded in May, 1995, catering to individual investors and institutions that werent getting the attention and service deserved, from larger firms. Brian started in the business as a fixed-income / credit analyst, with a Chicago broker-dealer, and then worked at Stein Roe & Farnham in Chicago, from 1992 - 1995, before striking out on his own and managing equity and balanced accounts for clients. Brian has a BSBA (Finance) from Xavier University, Cincinnati, Ohio, (1982) and an MBA (Finance) from Loyola University, Chicago, January, 1985. The CFA was awarded in 1994. Brian has been fortunate enough to write for the TheStreet.com from 2000 to 2012, and then the WallStreet AllStars from August 2011, to Spring, 2012. Brian also wrote for Minyanville.com, and has been quoted in numerous publications including the Wall Street Journal.
BQ started his career more than a decade ago as a trading algorithm developer and later became a research analyst. He currently manages a fund of family and friends, and is pursuing an entrepreneurial opportunity in the financial domain. Found the hard way that investing tended to return healthier and sustainable returns than day trading. He's an Electronics and Communications engineer, holds an MBA in Finance and writes mostly about Technology and Telecom companies.
"One of the best ways to do well in this business is to go to areas that have been unexploited by research capability and work them for all you can." -Julian Robertson
Bram de Haas lives with his girlfriend and baby son in The Netherlands/Nijmegen. Living in a city once a Roman settlement later bombed by allied forces in WO II he is aware of the vulnerability of Empires and the impact of the unexpected.
His investment style can be summed up as safety first. Once safe: be agressive.
Founder of Albright Investment Group, MBA graduate, active investor, and entrepreneur. I have a B.S. in management, and an MBA with a specialization in finance from top tier universities. I've been investing since 2002, and I enjoy writing about companies and topics that interest me. I manage a private long equity and ETF fund, and a secondary hedging/trading portfolio. I also host a very successful research service on Seeking Alpha, Albright Investment Group.
I am a motivated investor who has researches stocks for value and high potential for medium term growth. I expect a constant dividend from my investments and routine dividend hikes. I am not though a speculator and look for safe and proven stocks.
I am an investor basing my philosophy and analysis on determining intrinsic value of well-established companies. I believe in value, growth, and long-term investing. I am passionate about security analysis and hope to share valuable perspective on investing based on intrinsic value, financial stability, earning power, asset power, and reasonable long-term prospects, opposed to investing based on market speculation. I hope my contributions and analysis can be of value to fellow investors.
Finance professional in the Silicon Valley with a long/short-only, valuation-based approach to investing in high growth technology companies. Prior to joining the tech industry, covered software and internet companies on the sell side.
John Lonski is Managing Director and Chief Economist of Moody’s Capital Markets Group. His comments on credit market conditions and the business cycle appear daily in Moody’s CreditTrends and weekly in the Market Outlook publication of Moody’s Capital Markets Research Group.
John has appeared many times on CNBC, Bloomberg Television and Radio, Fox Business News, the Wall Street Journal Radio Network, the ABC Radio Network, PBS TV, and National Public Radio. He is also regularly cited in the Wall Street Journal, Barron’s, the Financial Times, Chicago Tribune, Los Angeles Times, Agence France Presse, the New York Times, and other leading publications.
A member of Blue Chip panel of economic forecasters, Mr. Lonski participates in a number of other forecasting surveys among which are the monthly pollings conducted by the Wall Street Journal, Bloomberg News, and Reuters, as well as the Philadelphia Federal Reserve’s semiannual Survey of Professional Forecasters.
Prior to joining Moody’s in February 1985, John was employed by the National Economic Research Associates (NERA). John holds a B.S. degree from Rensselaer Polytechnic Institute and, except for the dissertation, completed all of the requirements for a Ph.D. in economics from Michigan State University.
I am a student currently involved in research regarding neurodegenerative diseases at a large academic institution. I have recently taken up investing, and am interested in assessing the science basis for pharmaceutical products currently in clinical trials. As my work focuses primarily on providing scientific evaluations, the views I express in my posts should not be used as investment advice. I am not claiming to make explicit predictions regarding the outcome or performance of any product, and I work diligently to ensure that all of the information included in my work can be verified by an external source. I always welcome feedback, advice, and/or suggestions, so please do not hesitate to let me know where I may improve my work. Thanks!
Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaboration with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (“IBI) marketplace research is delivering robust returns since inception. To name a couple winners, Nektar Therapeutics and Spectrum Pharmaceuticals delivered profits of 446% and 196% for our subscribers, respectively. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios. Of note, we’ll increase our price soon (SUBSCRIBE to IBI now to lock in the current price and save money). Click the orange FOLLOW button to receive the FREE real-time alerts on our articles and blogs. To read the FREE once-weekly articles covering promising small-cap bioscience firms, check out www.drtranbiosci.com (and make sure to register for our mailing list). You can read up on Dr. Tran’s background in an in-depth article by following this link. http://www.drtranbiosci.com/p/dr-tran.html "Stellar therapeutics for patients. Differentiated intelligence for investors. Premium valuations for firms."
- Operates the "Insights For Future Wealth" Marketplace service, and IFFW Model Portfolio.
- Bachelor's degree in Business Administration with a concentration in Financial Analysis. Been investing and following the markets for more than a decade.
- A good hockey player plays where the puck is. A great hockey player plays where the puck is going to be.
- Wealth Insights is an investor, and investment author. His content is not geared to anyone's specific investment goals, time horizons, or risk tolerance. Content is for illustrative purposes only, and is not intended to displace advice from a fee based financial adviser. Accuracy of data is not guaranteed.
Investor/Trader in biotech and tech sectors for 10 years. Founder & Editor of ROTY (Runners of the Year), a strategy and now Marketplace Service focused on discovering opportunities to achieve high % gains within a year´s time frame.
Importantly, I often highlight risk management and entry/exit strategies, as I believe they represent areas that are often neglected but materially important for readers to understand and apply if they want to be profitable long term.
Learn more about the Small Cap model portfolio and the Prudent Biotech model portfolio at Graycell Advisors
Besides being an Analyst on both the Buyside and Sellside, the author has worked in Corporate Strategy and Finance roles for technology services companies and has now been publishing risk-adjusted return-driven quantitative model portfolios for many years at Graycell Advisors. More about the author can be learned here.
During 2016, the Graycell Small Cap Portfolio was up +71% compared to benchmark Russell 2000 Index gain of +19%. The Prudent Biotech Portfolio was up +7%, compared to Biotech Index (IBB) decline of -21% in 2016. In 2017, the outperformance continued, and so in 2018. Recent performance numbers are available here for Graycell Advisors and here for Prudent Biotech.
You are invited to take a look at our website for Samples, Performance, Philosophy, and Approach, and decide if the Biotech and Small Cap products can contribute to your investment objectives.
You can even Register for a Free Monthly Pick from the Biotech as well as Small Cap model portfolios.
Any questions, please write to Support @ GraycellAdvisors .com or use the Contact Form.
Graycell Advisors and related entities are not a Registered Investment Advisor (RIA). Nothing here or on the site constitutes a personalized investment recommendation, and stocks mentioned in the reports/articles/comments may be now or in the past, part of the portfolios recommended by Graycell Advisors and related entities. All opinions expressed are subject to change as new information develops, and no updates will be provided on model portfolios unless you are a subscriber. In addition, even though the author may not have a personal position in the stock names discussed, positions in such stocks may exist within related family and associates accounts.
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
The writer is a long term value investor and M.Sc graduate in Financial Markets with over 10 years experience. Value can be found in both long and short ideas and uses options to enhance the risk-return profile of investment ideas.
Disclaimer: This article provides opinions and information, but does not contain recommendations or personal investment advice to any specific person for any particular purpose. Do your own research or obtain suitable personal advice.
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases.
To contact Derek, email him directly: firstname.lastname@example.org (mailto:email@example.com)
Avisol Capital Partners runs the Total Pharma Tracker Seeking Alpha Marketplace service. This is managed by Dr Asok Dutta, BVScAH and Dr Udaya Kumar Maiya, MD Oncologist. The service offers end-to-end research on both investing and trading ideas everyday, and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked.
Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.
If you want to check out our service, go here - https://seekingalpha.com/author/avisol-capital-partners/research
Disclaimer - we are not investment advisors.
Pioneer of the PROVEN trading system BAD BEAT INVESTING, Quad 7 Capital, (parent company of Quad 7 Research, Quad 7 Partners, and Quad 7 Poker), was founded in 2017 by a team that consists of a long time investor, health researcher, financial author, professor, professional poker player, and politician. The BAD BEAT Investing Service is a top performer, focused on extreme value, and leveraging news driven events for rapid return swing trades.
The company has expertise in business, policy, economics, mathematics, game theory and the sciences. The company has experience with government, academia, and private industry. Quad7Capital.com covers a wide range of sectors and companies, with particular emphasis on news related items and mini-analyses on growth companies, cryptocurrencies, REITS, biotechnology/ pharmaceuticals, precious metals, blue chips and small-cap companies. It further offers money saving tips and market news.
Quad 7 Partners is the driving force behind the overall focus on current events, earnings, and timely developments, while Quad 7 Research aims to conduct several in depth analyses per month to identify misplaced market bets, and deep value situations. We are on Stocktwits, and Twitter under username _Quad7Capital_, and on Facebook and TalkMarkets under Quad7Capital.
@DavidAltonClark - Top Financial Expert per http://Tipranks.com
In addition to investing in and writing about stocks for the better part of the past decade, I'm currently a licensed Texas REALTOR® with 20 years in the business. I was formerly a FINRA registered securities representative in the oil and gas industry, worked in the banking industry, and as an auditor and consultant for a major accounting firm. I received my Bachelor's degree in Accounting (With Honors) from the University of Texas - San Antonio.
I've managed my portfolio for the past 25 years, including successfully navigating the 2000 and 2008 bubbles, so I understand the full cycle the market can take. My professional background has provided me with an intimate knowledge of corporate financial statements and how the companies actually made money.
I have been ranked #1 out of over 8500 financial bloggers and professional analysts tracked by TipRanks for a majority of the past three years. I am currently the most highly followed Financial Expert on TipRanks with over 6,300 followers. I have consistently been correct 75% of the time with my picks returning approximately 27.3% on an annual basis since 2011. I was thrilled to be featured in an article in BARRON'S for my stock picking performance in 2016.
Click this Globe and Mail and Barron's link for articles regarding my performance and background.
Brian is the founder of Investor in the Family and DIY Investing Summit.
At Investor in the Family (http://investorinthefamily.com/), Brian's goal is to help protect investors from making big mistakes that jeopardize their portfolios and financial futures.
The DIY Investing Summit (http://diyinvestingsummit.com/) was created to help link self-directed investors with carefully filtered and proven investing professionals to help save investors both time and money while building a portfolio that outperforms.
If you'd like to connect or learn more, please feel free to send a private message via Seeking Alpha platform.
Growth opportunities from different sectors related to technology. I provide deep value analyses of fundamentals that are driven by current and future trends. Day-trading experience since 2016. Masters: International Business and Finance in Hochschule Augsburg, Germany.
INDEPENDENT Financial Advisor / Professional Investor- with over 30 years of navigating the Stock market's "fear and greed" cycles that challenge the average investor. Investment strategies that combine Theory, Practice and Experience to produce Portfolios focused on achieving positive returns over a period of time. My soon to be launched Marketplace Service "The Savvy Investor" provides winning advice in helping to avoid the pitfalls and traps that wreak havoc on your portfolio with a focus on Income and Capital Preservation.
I manage the capital of only a handful of families and I see it as my number one job to protect their financial security. They don’t pay me to sell them investment products, beat an index, abandon true investing for mindless diversification or follow the Wall Street lemmings down the primrose path. I manage their money exactly as I manage my own so I don’t take any risk at all unless I strongly believe it is worth taking. Blogging here on SA is part of my research. I write to find out what I think. I invite you to join the family of satisfied clients send an e-mail :firstname.lastname@example.org
Gaurao is an MBA from Wales university and an engineering graduate from Mumbai university. He is involved in international trade and has been passionately tracking global equity markets for more than 7 years. He has been focusing mainly on spotting long term value investments in biotechnology, pharmaceutical, health insurance, hospital, and medical device sectors.
I am a biotech investor with a PhD in Biochemistry and Molecular Biology. I hope to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
I also collaborate with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively, or in advance. If you are interested, please click the link above!
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
To follow me click the "Follow" button! (Easy right?)
Kumquat Research is a college student and fund manager who has been investing for 6 years. He writes mostly about the technology sector and about event-driven and momentum opportunities across various industries and sectors. He is currently studying for degrees in both finance and computer science at the University of Maryland. Some of his interests include technology, programming, drumming, video games (developing and playing) and astronomy. Articles written and comments posted by Kumquat Research are NOT financial or investment advice, and only express his opinion. Do your own due diligence!
I'm an Army veteran and former energy dividend writer for The Motley Fool. My goal is to help all people learn how to harness the awesome power of dividend growth investing to achieve their financial dreams, and enrich their lives. With 22 years of investing experience, I've learned what works and more importantly, what doesn't, when it comes to building long-term wealth and income streams. I'm currently on an epic quest to build a broadly diversified, high-quality, high-yield dividend growth portfolio that:
1. Pays 5% to 6% yield
2. Offers 6% to 7% annual dividend growth
3. Pays dividends AT LEAST on a weekly, but preferably, daily basis